Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) PerCP/Cy55 Anti-mouse IFN-gamma Antibody     Product Data Sheet (PDF)    
PerCP/Cy5.5 Anti-mouse IFN-γ Antibody
3129105 25 µg $95.00       
3129110 100 µg $270.00       
Clone: XMG1.2
Isotype: Rat IgG1, κ
Reactivity: Mouse
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

ICFC - Quality tested

Application Notes:

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody as the capture antibody and recombinant mouse IFN-γ as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody as the detection antibody and recombinant mouse IFN-γ as the standard.

Recommended Usage:

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application References:

1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
7. Ferrick D, et al. 1995. Nature 373:255. (FC)
8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)

PMA/Ionomycin-stimlated ( 6hrs ) C57BL/6

PMA/Ionomycin-stimlated ( 6hrs ) C57BL/6 splenocytes surface stained with 145-2C11 (CD3) APC and intracellularly stained with XMG1.2 PerCP/Cy5.5


IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Cellular Sources: CD8+ and CD4+ T cells, NK cells
Cellular Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Bioactivity/Activities: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Antigen References:

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

This product or portions thereof is manufactured under license from GE Healthcare under U.S. Patent Numbers 5,268,486; 5,569,587; 5,627,027 and patents or pending applications that are continuations, continuations-in-part, re-examinations, divisionals, reissues or foreign equivalents thereof. THIS MATERIAL IS SUBJECT TO PROPRIETARY RIGHTS OF GE HEALTHCARE BIO-SCIENCES CORP. AND CARNEGIE MELLON UNIVERSITY AND MADE AND SOLD UNDER LICENSE FROM GE HEALTHCARE BIO-SCIENCES CORP. THIS PRODUCT IS LICENSED FOR SALE ONLY FOR RESEARCH. IT IS NOT LICENSED FOR ANY OTHER USE. THERE IS NO IMPLIED LICENSE HEREUNDER FOR ANY COMMERCIAL USE.
COMMERCIAL USE shall include:

  • sale, lease, license or other transfer of the material or any material derived or produced from it;
  • sale, lease, license or other grant of rights to use this Material or any material derived or produced from it;
  • use of this material to perform services for a fee for third parties.